FDA clears – On June 12, the FDA cleared Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children as young as 2—without insulin use—moving glucose tracking into phones, apps, and school and caregiver device rules.
On June 12. the FDA cleared Dexcom’s Stelo Glucose Biosensor System for children as young as 2 years old who do not use insulin. It’s a small line in a regulatory filing. but it changes the day-to-day reality for families and the systems that support them: glucose tracking now depends on apps. compatible phones. and clear rules about who sees the data—and what they do with it.
Dexcom’s Stelo brings over-the-counter continuous glucose monitoring into pediatrics, extending beyond its original March 2024 authorization for adults. With the clearance. families get a prescription-free option for app-based glucose tracking. rather than navigating the barriers that often come with pediatric medical devices.
The FDA clearance applies to people 2 years and older who do not use insulin. That includes children managing diabetes with oral medication and children using Stelo to understand how meals, activity, and daily routines affect glucose patterns.
Stelo works as a wearable sensor paired with an app on a compatible smartphone or smart device, including a caregiver’s phone. The app displays glucose values and trends every 15 minutes. It is not a standalone meter, and it does not issue low-glucose alerts.
The conditions where Stelo is not for users are just as important. Stelo is not for people who use insulin, people with problematic hypoglycemia, or people on dialysis. It also should not be used by children to make medication changes based on readings without medical guidance. For children, the guidance is clear: Stelo should be used under adult caregiver supervision.
It also comes with a specific caution for a sensitive group. People with a history of disordered eating or eating disorders should consult a healthcare provider before use.
That combination—data on phones, no low-glucose alerts, and restrictions tied to medical situations—creates a new kind of operational challenge for everyone who will be around the device: health care teams, schools, and benefits administrators.
The change isn’t only about clinical eligibility. Stelo depends on a connected workflow: a sensor. app access. a compatible operating system. and proximity to a phone or smart device. That matters because broader Android system updates can still affect app controls. setup. backups. and security checks—even though Stelo is now over the counter.
Dexcom’s Stelo app compatibility page lists minimum iOS and Android requirements for phones. A smartwatch can work as an app extension, but only when connected to and within range of the phone—mirroring a phone-first approach seen in many Apple Watch glucose monitoring apps.
For school administrators and IT teams. the practical question is immediate: can the device work reliably in the environment where rules are strict?. Schools with cellphone restrictions. limited Wi‑Fi access. or device limits during class and testing may need to write new policies for wearable health monitoring that depends on caregiver-connected phones remaining nearby.
The same issue follows glucose data through the school day. Health administrators may need to decide whether caregiver-connected phones can stay within range during class and testing, whether Wi‑Fi and phone rules allow the app workflow to function, and who—if anyone—responds to glucose readings.
Healthcare organizations face a different but related task. With OTC status removing the prescription barrier, screening still has to be disciplined. Stelo may not be appropriate for children who use insulin, have problematic hypoglycemia, or need real-time low-glucose alerts.
Even the timeline of the wearable itself comes with nuance. Each sensor lasts up to 15 days, though wear time may be shorter in pediatric users. The FDA said it used prior clinical study data and real-world evidence from current integrated CGM users to assess pediatric performance.
Pricing, reimbursement, and pediatric rollout details still need verification—so families and institutions are left with the core decision points for now: caregiver oversight, device access, and clear rules for what glucose tracking will mean in real life.
As glucose monitoring moves deeper into everyday apps and smart devices, June 12 marks the regulatory green light. The harder work now lands with the people and systems that have to make it safe, workable, and understood—without turning a medical signal into a confusing new responsibility.
FDA clearance Dexcom Stelo over-the-counter continuous glucose monitor pediatric glucose tracking app-based diabetes monitoring iOS Android compatibility school IT policies caregiver supervision glucose sensor
So does this replace regular finger pricks or is it just for vibes??
Kinda wild the FDA cleared it for kids as young as 2. But if it doesn’t even do low alerts, what’s the point during nighttime? Also my cousin said Dexcom is always basically working with Apple so…idk.
Wait it says “first over-the-counter continuous glucose monitor for children” but then it says it’s not for insulin users? So like for most diabetes kids it’s not even usable? I’m confused. Feels like another tech thing where parents still gotta fight with paperwork.
As long as the school/caregiver data rules are clear then cool. But knowing how apps are, I’m sure some phones won’t be “compatible” and then you’re stuck. Also why is everyone acting like it’s a game changer when it’s basically trends every 15 minutes… unless the internet kids are doing it differently now.